ASX Announcement

Medibio Limited – 30 January 2018



Medibio to announce second quarter FY18 update and cashflow

Sydney, Australia and Minneapolis, MN – 30 January 2018: Medibio Limited (MEB or the Company) (ASX: MEB) (OTCQB: MDBIF), today announced that its second quarter financial year 2018 update and cash flow report will be released on Wednesday, January 31, 2018.

An earnings teleconference is scheduled for 11:00am Australian Eastern Daylight Time on Thursday, 1 February 2018 and will be accessible via the below dial in details and on Medibio's Investor Relations website at https://medibio.com.au/investors.

To dial in to the audio only conference call please use either the telephone numbers or the webcast URL provided below.

Australia: +61 3 8488 8990 United States: +1 951 384 3421 Access Code: 813 102 894

URL: https://attendee.gotowebinar.com/register/4714070730494392065 After registering, you will receive a confirmation email containing information about joining the webinar.

Please note that all questions can be submitted via the following email address on stephanie.ottens@medibio.com.au and will be addressed throughout the call or specifically at the end of the call if required.

A replay of the webcast will be available after the event and accessible via the webinar address above.

- ENDS -

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices located in Melbourne (Vic), and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Further Information:	Website: <u>www.medibio.com.au</u>
Medibio Shareholder Enquiries:	Australian Media Enquiries:
Stephanie Ottens	Peter Taylor
Investor Relations Director	NWR Communications
Medibio Limited	peter@nwrcommunications.com.au
stephanie.ottens@medibio.com.au	T: +61 (0) 412 036 231
T: +61 434 405 400	